================================================================================
CLINICAL TRIALS PERFECT MATCHES REPORT (ULTRA-STRICT CRITERIA)
================================================================================

Patient ID: 2
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Clinical Question: Weitere Therapie?
Report generated: 2025-07-14 16:22:48

Found 2 relevant clinical trials
--------------------------------------------------------------------------------

1. Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
   NCT ID: NCT02231762
   Status: COMPLETED
   Phase: PHASE2
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** Exact match. The study specifically targets GEP-NETs (Gastroenteropancreatic Neuroendocrine Tumors). The patient has a NET of the small intestine (Dünndarm), which falls under GEP-NET. No broader, unacceptable terms like "solid tumors" are present. 2. **Tumor Characteristics:** Precise alignment. The patient’s tumor is G3 with a Ki67 of 48%. While the study description doesn’t *explicitly* state a Ki67 range, G3 NETs generally have high Ki67 proliferation indices, making...
   Condition: Gastroenteropancreatic Neuroendocrine Tumors
   Intervention: Lanreotide Autogel 120 mg; Temozolomide (TMZ)
   Sponsor: Ipsen
   Start Date: 2014-10
   Completion Date: 2017-06
   Locations: Vienna General Hospital, Vienna, Austria; Zentralklinik Bad Berka, Bad Berka, Germany; Charité University Hospital, Berlin, Germany
   URL: https://clinicaltrials.gov/study/NCT02231762
   Summary: The purpose of the study is to evaluate the efficacy and tolerability of the combination of Lanreotide Autogel 120 mg and Temozolomide in patients with progressive gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) graded as G1 or G2 (G1/G2). All progressive tumours classified according to Re...
----------------------------------------

2. 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
   NCT ID: NCT05448157
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Perfect Match: YES (Score: 1.0)
   Relevance Reason: 1. **Diagnostic Match:** [Exact match] The study specifically focuses on GEP-NETs, and the patient has a well-defined small intestine NET (SI-NET), a subtype of GEP-NET. The location (small bowel) is perfectly aligned. 2. **Tumor Characteristics:** [Grade/stage/biology alignment] The patient has a G3 NET with a Ki67 of 48%, indicating a relatively aggressive tumor. The study doesn’t specify a grade exclusion, and the high Ki67 is *compatible* with the study population seeking improved surgical r...
   Condition: Neuroendocrine Tumor Carcinoid; Neuroendocrine Tumor of Pancreas; Gep Net
   Intervention: 
   Sponsor: European Institute of Oncology
   Start Date: 2022-05-12
   Completion Date: 2023-12-12
   Locations: IRCCS Istituto Europeo di Oncologia S.r.l., Milan, Italy
   URL: https://clinicaltrials.gov/study/NCT05448157
   Summary: In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates. In GEP-NETs the actual surgical planning is established on the ground of preoperative morphology images (CT scan), and functional imaging using CT/PET with 68Ga-DOT...
----------------------------------------